Business Wire

TX-MARY-KAY

Share
Mary Kay Inc. Expands Partnership with The Nature Conservancy to Protect Waterways Across the Globe

Last year, Mary Kay Inc ., an international leader in corporate and social responsibility, announced the company had partnered with The Nature Conservancy to protect Texas fisheries and the Gulf of Mexico . Today, Mary Kay is proud to announce they’ve expanded that partnership with The Nature Conservancy to impact waterways—and native species—the world over.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200716005038/en/

“All life on Earth began in and depends on our oceans,” said Deborah Gibbins, Chief Operating Officer at Mary Kay. “Water is the most valuable resource on our planet, and it’s essential that we do our part to protect it. When we began scaling our partnership with The Nature Conservancy last year, we focused on the waterways surrounding our home state of Texas. But we’re a global company, and we knew the need for support stretched far beyond the Gulf of Mexico. We’re thrilled to advance ecosystems and biodiversity conservation globally.”

Founded in 1951, The Nature Conservancy is the leading conservation organization, working around the world to protect ecologically important lands and waters for nature and people. The Conservancy’s practices are rooted in science and are driven by pragmatic solutions to the most pressing conservation threats at the largest scale.

The conservation programs are as vast and diverse as the ocean life they’re designed to protect. Beyond the Texas fisheries program, Mary Kay will also support The Nature Conservancy through the following programs:

  • Australia: In Northern Australia, Mary Kay will partner with indigenous communities to increase women’s role in conservation, including refining community-based healthy spatial development, working with government and non-government partners to scale up the adoption of conservation tools, and establishing a women’s camp at Fish River Station, a 445,000-acre property in the Northern Territory.
  • New Zealand: In New Zealand, Mary Kay and The Nature Conservancy will engage with indigenous people in sustainable aquaculture, including supporting the implementation of restorative activities in Auckland’s Hauraki Gulf to restore wild shellfish populations and launching a challenge fund to encourage greater philanthropic support for restoration of wildlife.
  • Mexico: In Mexico, Mary Kay and The Nature Conservancy will partner on the Monterrey Water Fund, which will enhance watersheds and support women in the area. These improvements include irrigation systems, a substrate study, and the diversification of plant production.
  • China: In China, Mary Kay and The Nature Conservancy will work to protect rural headwaters to secure clean drinking water for millions of people across the country. By 2021, the team will demonstrate five headwater production projects in Zhejiang, Fujian, Guangdong, and one other province.
  • General Ocean: The partnership will also mitigate plastic pollution in Indo-Pacific tuna fisheries. Together, they will work with leading plastic researchers to identify the fisheries that are the biggest contributors to ocean pollution so high-impact pilot programs and be put in place to mitigate pollution and clean up our seas.
  • Solomon Islands: In the Solomon Islands, the partnership will protect turtles through female-led ecotourism of the South Pacific Ocean. Mary Kay’s contribution will help create a viable, locally-run ecotourism venture in the Arnavon Islands that strengthens turtle conservation and provides equitable, sustainable financial returns to communities that are best positioned to protect endangered species.
  • Colombia: Through the Bogota Water Fund, the partnership will improve water security for millions of people in Colombia.
  • Canada: In Canada, Mary Kay and The Nature Conservancy will strengthen indigenous stewards by supporting current and future community leaders in traditional territories. This is an investment in a healthy future for these communities, their lands and waters for future generations.
  • Europe: In the UK and Germany, the partnership will work to protect biodiversity and marine resources as they introduce the native European oyster. In Spain, the partnership will work to create a water fund—the country currently faces some of the worst challenges in terms of water scarcity and water quality.

“We need healthy, diverse oceans for fishing, working and playing,” said Lily Verdone, Director of Freshwater and Marine at The Nature Conservancy. “But protecting oceans is about more than just protecting our planet: oceans add $1.5 trillion to the global economy each year. Mary Kay has long worked to impact change that will sustain the earth for generations to come, so they are a natural—and welcome—partner for The Nature Conservancy. We’d already seen such impactful change in Texas, and we’re thrilled to see what their contributions will help us accomplish in communities across the world.”

Mary Kay also sponsored EarthxOcean conference, a livestreaming event that brought experts, researchers and conservations together in a livestream to discuss topics such as the High Seas Initiative, coral reef restoration, ocean plastic solutions and sustainable fisheries.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 55 years ago with three goals: offer rewarding opportunities for women, manufacture irresistible products and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to researching the science behind beauty and to manufacturing cutting-edge skin care, color cosmetics and nutritional supplements. Through the Mary Kay FoundationSM , the company has awarded more than $78 million to cancer research and domestic violence shelters. Mary Kay Ash’s original vision continues to shine—one lipstick at a time.

About The Nature Conservancy

The Nature Conservancy is a global conservation organization dedicated to conserving the lands and waters on which all life depends. Guided by science, we create innovative, on-the-ground solutions to our world's toughest challenges so that nature and people can thrive together. We are tackling climate change, conserving lands, waters and oceans at an unprecedented scale, providing food and water sustainably and helping make cities more sustainable. Working in 79 countries and territories, we use a collaborative approach that engages local communities, governments, the private sector, and other partners. To learn more, visit www.nature.org or follow @nature_press on Twitter.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release

The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki

Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release

Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee

DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release

Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release

SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye